Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy: Previous trial results showed signficant improvements in radiographic PFS and OS from adding apalutamide to ADT. The FDA recently approved the drug for metastatic castration-sensitive prostate cancer.

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News